The aim of this study was to investigate the immunomodulatory effects and mechanism of action of alpha-melanocytestimulating hormone (a-MSH) gene modified proteolipid protein ( infiltrates, a pronounced decrease in Th1 cytokines and chemokines expression and an increase in Th2 cytokines. These data strongly suggested that local delivery of a-MSH by rAAV2-mediated a-MSH-transduced PLP139-151-specific T cells (T PLP-a-MSH ) would be a desirable new approach to the treatment of autoimmune disease in the CNS.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) with a relapsing-remitting or a progressive course. Experimental autoimmune encephalomyelitis (EAE), an animal model of MS, is a paralytic and often demyelinating disease of the CNS, induced by immunizing susceptible animals with myelin antigens or peptides (i.e., proteolipid protein (PLP) 139-151, myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) , or by adoptive transfer with activated myelin Ag-specific T cells. 1 EAE has been widely employed to explore pathogenic mechanisms underlying MS. 2, 3 The generation of myelin protein-reactive T cells is an immunological hallmark of both EAE and MS and is required for disease expression in EAE. These autoreactive T cells traffic to the CNS and initiate inflammation and destruction of CNS myelin, resulting in neurological impairment. 4, 5 In this model, self-reactive CD4+ T cells produce interleukin-2 (IL-2) and interferon (IFN)-g, T helper (Th)-1 cytokines that is believed to facilitate disease progression, whereas Th2 cells and cytokines, namely IL-4 and IL-10, have been shown to reduce its severity.
Genetic modification of myelin protein-specific T cells have provided a means for both identifying and delivering therapeutic transgene factors capable of modulating inflammation. Autoreactive T cells can be genetically altered with viral vectors to produce therapeutic transgene proteins in a nonconstitutive, antigen-inducible manner, resulting in decreased severity of clinical and histological autoimmune demyelinating disease. [6] [7] [8] [9] [10] [11] Adeno-associated virus (AAV) is a nonpathogenic parvovirus that infects a wide variety of cells, both in vitro and in vivo. 12, 13 Recombinant adeno-associated viruses 2 (rAAV2) are important tools for gene delivery and expression as they have been used as vectors for direct in vivo genetic immunization 14, 15 and possess several potential advantages for gene transfer. Advantages of rAAV2 include the ability to transduce both dividing and nondividing cells, the absence of viral coding sequences as well as the capacity for persistent transgene expression, which can last for the life of the transduced cell. 16 a-Melanocyte-stimulating hormone (a-MSH) is a neuroimmunopeptide that plays a crucial role in the regulation of immune and inflammatory reactions. 17, [19] [20] [21] Studies suggest that a-MSH promotes the restoration of injured nerves and the spinal cord. 18 Research also suggests that a-MSH may inhibit the production and activity of proinflammatory cytokines, while enhancing the secretion of anti-inflammatory cytokines. a-MSH is an endogenous peptide without evident toxicity and has been demonstrated to be safe when given in large and continuous doses to animals and humans. [19] [20] [21] However, it is very unstable in vivo and its therapeutic use would require daily administration. Yin and co-workers have created two DNA expression constructs (miniPOMC and pACTH1-17) that encode bioactive versions of the a-MSH peptide, and have tested these constructs for their therapeutic effects in EAE. 22 Their results suggested that although bioactive peptides were secreted from cells transfected with either construct, there appeared to be a significant therapeutic effect only with pACTH1-17, which contained an extra C-terminal amino acid. However, in order to obtain satisfactory therapeutic effects, the use of a-MSH or expression constructs required repeated injections.
In this report, active relapsing-remitting EAE (REAE) was used to investigate the therapeutic effects and related mechanisms of action of a-MSH gene-modified PLP139-151-specific T cells (T PLP-a-MSH cells), which were prepared by transfecting PLP139-151-T cells with rAAV2 carrying the a-MSH gene (rAAV2-a-MSH). The aim of this study was to explore its effectiveness as a potential gene therapy treatment against chronic autoimmune inflammation and demyelination diseases of the CNS as well as other autoimmune disorders.
Results

Characterization of a-MSH-transduced PLP139-151-specific T cells
A vector (rAAV2) encoding either a-MSH (rAAV2-a-MSH) or green fluorescent protein (hrGFP) (rAAV2-hrGFP) (Figure 1 ) was used to confirm transduction of PLP139-151-specific T (T PLP ) cells by transgene expression. a-MSH gene-modified T PLP cells (T PLP-a-MSH cells) or hrGFP reporter gene-modified T PLP cells (T PLP-hrGFP cells) were prepared by infecting T PLP cells with either rAAV2-a-MSH or rAAV2-hrGFP, respectively, on day 3 of cell culture. Fluorescence microscopy of GFP reporter gene expression was used to estimate the percentage of transduced T PLP cells. Our results suggested that the ideal multiplicity of infection (MOI) was 4 Â 10 5 vector genomes (v.g.)/ml ( Figure 2a ) with a transduction rate of 30-35% (Figures 2b and c) .
The ability of T PLP-a-MSH cells to produce a-MSH was also investigated. Serum-free culture media from PLP139-151-activated T PLP-a-MSH cells, T PLP-hrGFP cells or T PLP cells were analyzed for a-MSH contents utilizing an EIA kit (the lowest sensitivity is 30 pg/ml). Secretion of a-MSH by T PLP-a-MSH cells was detected 2 days after PLP139-151 stimulation and was time dependant, whereas secretion by T PLP or T PLP-hrGFP cells was barely detectable above the serum-free medium background (o30 pg/ml) ( Figure 3 6 cells/mouse) resulted in an EAE incidence rate of 100%. In contrast, under the same conditions, the incidence of EAE induced by equal amounts of T PLP-a-MSH was 12.5% (1/8), the onset time was prolonged from 7 days to 13 days, and the clinical score was significantly decreased (Table 1) . A limp tail was the only symptom noted in the group receiving T PLP-a-MSH cells. These results suggested that the ability of T PLP-a-MSH cells to cause encephalitis had markedly declined.
Effect of T PLP-a-MSH cells on relapsing-remitting EAE
In order to evaluate the prophylactic and therapeutic potential of a-MSH-transduced PLP139-151-specific T cells, T PLP-a-MSH or T PLP-hrGFP cells were activated by exposure to PLP139-151 3 days before cell transfer, then adoptively transferred into SJL mice (5 Â 10 6 cells/ mouse). When transduced cells were injected simultaneously with the REAE induction, activated T PLP-hrGFP cells slightly accelerated the development of REAE in PLP139-151-immunized SJL recipients. In contrast, the activated T PLP-a-MSH cells caused a significant reduction in incidence of REAE, as well as a marked delay of onset, resulting in a decrease in the REAE score of recipients (Figure 6a) . A significant protective effect was still seen when activated T PLP-a-MSH cells were injected (13 days postimmunization (dpi)), 2 days after the onset of REAE, The content of a-MSH in the sera as well as in the CNS increased 24 h after the transfer of T PLP-a-MSH cells (13 dpi) . High levels of a-MSH in the sera were sustained for 4 days then gradually declined to normal (Figure 8a) . The a-MSH content in the CNS peaked 4 days after injection, with consistently high levels a-MSH maintained for a period of at least 1 week (Figure 8b ). Similar effects were not seen in the phosphate-buffered saline (PBS)-treated group or in the T PLP-hrGFP cell-treated group. 
Prevention and treatment of EAE with rAAV a-MSH D Han et al
It is well known that activated, autoaggressive T cells fail to attack the CNS immediately after transfer. The formation of an inflammatory infiltrate and associated tissue damage require a lag phase of at least 3 days. In order to explore the homing activity and the distribution of T PLP-a-MSH cells in SJL mice, the expression of hrGFP DNA in different tissues following T PLP-a-MSH cell transfer was detected by PCR amplification using hrGFP-specific primers. The results demonstrated that the expression of hrGFP was detected in the blood, spleen and lymph nodes at 72 h, peaking at 96 h, then gradually declining (data not shown). While minimum expression of hrGFP was detected in the CNS at 72 h, peaking at 120 h, its expression was still detected in the CNS eight days after T PLP-a-MSH cell transfusion (Figure 9a ). The expression of hrGFP DNA in REAE mice was detected in the CNS 24 h after T PLP-a-MSH cell transfusion, peaking at 96 h, and was sustained for approximately 2 weeks (Figure 9b ).
We further investigated the mechanism of action of T PLP-a-MSH cells. No significant change in the levels of IL-2, IFN-g, IL-10 and TGF-b were noted in the serum or in the CNS of the T PLP-hrGFP cell group, compared with PBStreated controls ( Figure 10 ). While the IL-2 and IFN-g content decreased in the T PLP-a-MSH cell treated group, levels of IL-10 and TGF-b were higher than those seen in the two former groups. The intracellular cytokine expression in CD4 + T cells, among the individual mononuclear cells within the CNS of REAE mice, is illustrated in Figure 11 . In a typical experiment, a substantial fraction of CD4 + T cells (425%) produced IL-10, although few cells expressed IFN-g (o15%) in the T PLP-a-MSH cell treatment group. These results suggested that adoptively transferred T PLP-a-MSH cells inhibited the secretion of Th1-type cytokines and enhanced the production of Th2-type cytokines.
Additionally, we found there were distinct differences in the expression of monocyte chemoattractant protein-1 (MCP-1), regulated on activation normal T cell expressed and secreted (RANTES) and macrophage inflammatory protein-2g (MIP-2g) mRNA within the CNS of REAE mice, depending on the phase examined. The mRNA expression of all three chemokines was enhanced at the onset, declined during the peak and the remitting phase, but was enhanced during relapse. Interestingly, chemokine mRNA expression declined during the relapse phase in T PLP-a-MSH cell-transferred mice ( Figure 12 ). These data suggested that a possible mechanism of action of T PLP-a-MSH cells was to reduce the expression of chemokines that functioned as chemoattractants of inflammatory cells.
Discussion
Although many cell types are currently being studied as vehicles for gene therapy, the intrinsic tissue-specific homing properties of autoantigen-specific T cells make them attractive vectors and ideal vehicles for site-specific transgene delivery. Studies have demonstrated that genetically engineered cell vectors can survive long term and produce therapeutic concentrations of proteins capable of inhibiting CNS-inflammatory diseases.
6-11 It Prevention and treatment of EAE with rAAV a-MSH D Han et al has been previously reported that DNA expression constructs (miniPOMC and pACTH1-17), that encode bioactive versions of the a-MSH peptide, ameliorated EAE. 22 However, DNA construct production time was limited and required multiple injections to achieve preventive effects. In contrast, our current study demonstrated that the use of an adeno-associated viral (AAV)/ cell vector system resulted in transgene production that could be detected for at least 2 weeks. We also demonstrated that rAAV2-mediated a-MSH-transduced PLP139-151-specific T cells (T PLP-a-MSH ) had reduced encephalitogenic capacity and protected against PLP139-151-induced REAE in SJL mice, even when given during the development of disease symptoms.
A significant difference noted between T PLP-a-MSH cells and untransduced T PLP or T PLP-hrGFP cells was the enhanced production of a-MSH by T PLP-a-MSH cells. We compared the in vitro responsiveness, the migratory behavior and functional state upon transfer in vivo of these groups of encephalitogenic T cells. Additionally, we measured their capacity to infiltrate CNS tissues and their effects on local reactivation within the CNS. In vitro data demonstrated that T PLP and T PLP-GFP cells, which transfer severe clinical EAE to syngeneic hosts, upregulated two activation markers, CD25 and CD28, as well as increase of CD3 and MHC class II molecules on their surface. Additionally, these cells triggered IL-2 and IFN-g production. These functional changes closely resemble antigen-dependent T-cell activation in vitro. Flugel et al. Prevention and treatment of EAE with rAAV a-MSH D Han et al altered after transduction with a-MSH, as cells lost their capacity to transfer EAE to SJL recipients and gained the ability to significantly ameliorate the development of actively induced EAE in SJL mice. Our study suggested that the in vitro properties of these cells were completely changed by having been engineered to produce more a-MSH than they normally would produce. More importantly, the frequency of CD4 + CD25 + cells among T PLP-a-MSH cells was markedly enhanced compared to T PLP and T PLP-GFP cells (Figure 5b 
24-26
Induction of suppressor activity requires that CD4 + CD25 + cells be activated through their TCR. However, once activated, they suppress T-cell activation in an antigen-independent manner, without a requirement for reactivation through their TCR. Taylor and co-workers [27] [28] [29] have reported that a-MSH could induce the production of Treg cells; however, the mechanisms of suppression by the a-MSH-induced Treg cells is not yet clear. Further research is needed to elucidate the specific role of CD4 + CD25
+ T PLP-a-MSH cells compared to total T PLP-a-MSH cells in the treatment of REAE.
After systemic delivery of T PLP-a-MSH cells, high levels of a-MSH were detected in the CNS compared to that noted in the peripheral compartments. The capacity of a-MSH to maintain a concentration gradient of immunosuppressive agents within the CNS, as well as its very short half-life, may be important to limit nonspecific effects in the periphery. In the current study, the use of antigen-specific hrGFP-expressing T cells offered several experimental advantages. Effector cells in the CNS could be easily identified and isolated with the use of hrGFP, a self-replenishing fluorescent marker. Invasion of hrGFPexpressing effector T cells into the CNS was confirmed by reverse transcription-polymerase chain reaction (RT-PCR), which yielded slightly higher estimates of T GFP cells than cytofluorometric analyses owing to its greater sensitivity. 30 CNS infiltration of hrGFP + T cells was detected in adoptive transfer EAE mice, 4 days after the transfer of T PLP-hrGFP or T PLP-a-MSH cells, with peak levels noted at day 6, then abruptly falling on day 8 (Figure 9a ). In active REAE mice, hrGFP + T cells in the CNS were detected 24 h after transfer and peaked 3-4 days later, with peak levels sustained for at least 2 weeks (Figure 9b ). These data suggested that the level and the time course of the production of a-MSH and the expression of hrGFP resulted in similar physiologic outcomes. 
T PLP cells, T PLP-a-MSH cells or T PLP-hrGFP cells (3 days after activation with PLP139-151 in vitro,
20 mg/ml, 5 Â 10 6 cells/mouse) were injected into mice immunized with PLP139-151/CFA 13 dpi. The content of a-MSH in the sera and the supernatant of CNS tissue homogenate was detected using an EIA kit. *Po0.05; **Po0.01 compared to T PLP-hr-GFP cell-transferred mice.
Prevention and treatment of EAE with rAAV a-MSH D Han et al
Studies have shown that inflammatory CD4
+ T cells that mediate EAE secrete Th1 cytokines, including IL-2, IFN-g and TNF. In contrast, Th2 cells secrete IL-4, IL-5, IL-6, IL-10, IL-13 and TGF-b, are thought to downregulate EAE. Additionally, some cytokine genes, such as IL-4, 6 IL-10 6,7 and TGF-b1, 8, 11 have been used to genetically engineer PLP-or MBP-specific T cells to protect against EAE induction. Studies have shown that a-MSH has multiple anti-inflammatory properties. 17, 19, 20, 28, 29 More recently, Wang et al. 31 reported that electroporative a-MSH gene transfer attenuates thioacetamide-induced murine hepatic fibrosis by matrix metalloproteinase (MMP) and tissue inhibitors of matrix metalloproteinase (TIMPs) modulation. The peptide acts through cell surface receptors to reduce the production of proinflammatory mediators, such as TNF-a, nitric oxide, IL-1 and IL-6 and downregulates immunomodulating cytokines, such as IL-2, IL-4, IL-13 and IFN-g. Conversely, it upregulates IL-10 and TGF-b (Figure 10 ). The ability of T PLP-a-MSH cells to reduce the relapse rate and severity of REAE in SJL mice may have resulted from this cytokine switch.
In addition, a positive correlation between the temporal expression of MCP-1, RANTES and MIP-1a in the CNS and the inflammatory response in animals with EAE has also been previously described. 32 Moreover, antibodies directed against these chemokines suppressed disease in adoptive transfer and active EAE. 33, 34 Our finding that T PLP-a-MSH cells failed to induce strong MCP-1, RANTES and MIP-2g responses in the CNS correlated well with the low numbers of infiltrated inflammatory cells recruited into the CNS and may have been due to the weak production of IFN-g in the CNS. Previous studies have demonstrated that a-MSH downregulated the LPS-induced expression of E-selectin and vascular cell adhesion molecule-1 on human microvascular endothelial cells. 35 Downregulation of the expression of these inflammatory chemokines and adhesion molecules may be one of the mechanisms of action of T PLP-a-MSH cells that confer protection against REAE.
Our studies led us to conclude that the production of a-MSH confers immunomodulating properties to autoreactive T cells, allowing them to regulate other inflammatory cells in their immediate vicinity. We also propose that genetic engineering of self-reactive T cells with a-MSH may represent a clinically viable approach to the treatment of autoimmune diseases.
Materials and methods
Vector construction
The pAAV-IL-2sp-a-MSH-hrGFP plasmid was constructed utilizing the Stratagene AAV-free helper system (Stratagene, La Jolla, CA, USA) containing pHelper, pAAV-RC and pAAV-IRES-hrGFP plasmids, following the manufacturer's instructions. Briefly, the pGEM-IL2sp plasmid, representing the DNA fragment corresponding to the encoding region of human IL-2 signal peptide (48-107) was obtained from acute T-cell leukemia Jurkat cDNA by reverse transcription-PCR, using the sense primer of 5 0 -GGAATTCATGTACAGGATG CAACTCCTGCCGGCGGTACCG-3 0 and the antisense primer of 5 0 -CGGTACCGCCGGCACTGTTTGTGACAA GTGCAAGAATTCC-3
0 . An EcoRI restriction site was added before the start codon and a NaeI-KpnI site was introduced for in-frame ligation with a-MSH cDNA (underlined sections of primers). After digesting the amplified fragment with EcoRI and KpnI, the resulting fragment was ligated into a multiple cloning site (EcoRI/ KpnI) of the pGEM-3Zf vector (Promega, Madison, WI, USA) to construct the pGEM-IL-2sp-a-MSH plasmid. a-MSH cDNA was obtained by annealing 5 0 phosphorylated oligonucleotides 5 0 -GGCAGTTATAGTATGGAG CACTTCAGGTGGGGAAAGCCAGTAG-3 0 and 5 0 -GTA CCTACTGGCTTTCCCCACCTGAAGTGCTCCATACTA TAACTGCC-3 0 and cloned into the pGEM-IL-2sp vector at the NaeI and KpnI sites. Owing to the fact that the IL-2sp-a-MSH fragment was smaller than 1 kb, which would potentially influence viral packaging efficiency, a 'stuffer' DNA (1 kb) was cloned into pGEM-IL-2sp-a-MSH vector at the KpnI and XhoI sites to produce an insert that would be X1 kb. Following digestion of the pGEM-IL-2sp-a-MSH vector with EcoRI and XhoI, the resulting fragment was ligated into a multiple cloning site (EcoRI/XhoI) of the pAAV-IRES-hrGFP vector (Stratagene, USA), resulting in the pAAV-IL-2sp-a-MSHhrGFP plasmid (Figure 1 ). All vectors were confirmed by DNA sequencing. Escherichia coli BL21 competent cells (BD Biosciences Clontech, Palo Alto, CA, USA) were used for plasmid amplification and hamster embryonal kidney cells (HEK 293, ATCC, Washington, DC, USA) were used for virus production.
Packaging of rAAV
Packaging of mature virions was performed in 293 cells by calcium phosphate plasmid transfection, follow- ing the manufacturer's instructions. A pAAV-IL-2sp-a-MSH-hrGFP plasmid was used for the production of rAAV-a-MSH and rAAV-hrGFP encoding a humanized recombinant hrGFP in conjunction with the pAAV-IREShrGFP plasmid. Cotransfection of 293 cells with the respective rAAV plasmids, pAAV-RC and the pHelper plasmid was utilized for packaging of rAAV, according to the manufacturer's instructions (Stratagene, Catalog #240071). Briefly, cells were harvested 60 h post-transfection and lysed by freeze/thaw (3 Â ). Further AAV purification utilized CsCl density gradient centrifugation (twice) as described as Grimm and co-workers. 36 DNase I treatment of viral preparations was performed to digest unencapsidated DNA. rAAV v.g. quantitation was determined through dot-blot hybridization using horseradish peroxidase-labeled hrGFP gene as a probe, and compared to the pAAV-IRES-hrGFP control plasmid.
Titers of AAV vector stocks used were estimated to be 10 12 -10 13 v.g./ml. Transduction activities of the vectors were assessed by infecting AAV-HT1080 cells, a human fibrosarcoma cell line (Stratagene), for 8 h in serum-free media with serial dilutions of each vector (1 Â 10 8 -1 Â 10 12 v.g./well, 12-well plates, 3 Â 10 5 cells/well). Media were then replaced with fresh media containing 10% fetal calf serum (FCS). Fluorescence microscopy was used to count the number of cells expressing hrGFP 48 h after transduction, so as to measure the transferring unit of rAAV.
Induction of EAE
The CNS target peptide, PLP139-151 (HSLGKWLGHPDKF), was obtained from New England Peptide (Fitchburg, MA, USA). The purity of the peptide was greater than 95% as measured by amino-acid IFN-γ Figure 11 Intracytoplasmic detection of IL-10 (upper row) and IFN-g (lower row) in mononuclear cells within the CNS. Cells were restimulated with phorbol 12-myristate 13-acetate and ionomycin for 6 h in the presence of Brefeldin A before staining. Cells were then fixed, permeabilized and processed for double immunocytochemical staining, using primary mAbs specific for murine cytokines IFN-g or IL-10, revealed by PE-conjugated anti-rat Igs, followed by FITC-conjugated anti-CD4. n ¼ 3 separate experiments.
MCP-1 RANTES MIP-2γ
T PLP-hrGFP cells-treated REAE T PLP-α-MSH cells-treated REAE GAPDH PBS treated REAE 0dpi 11dpi 18dpi 25dpi 32dpi 0dpi 11dpi 18dpi 25dpi 32dpi 0dpi 11dpi 18dpi 25dpi 32dpi Figure 12 Chemokine gene expression of MCP-1, RANTES and MIP-2g on CNS tissues. Representative mice (n ¼ 12) from onset (11 dpi), peak (18 dpi), remission (25 dpi) and relapse (32 dpi) phases of EAE, from PBS, T PLP-hrGFP cells and T PLP-a-MSH cells-treated groups were used for analysis of chemokine gene expression. RNA from spinal cord was analyzed by RT-PCR using specific primers for MCP-1, RANTES and MIP-2g, or GAPDH. DNA amplification products were analyzed by gel electrophoresis identified bands at 535, 463 and 200 bp. Note increased levels of chemokine RNA in PBS and T PLP-hrGFP cell-treated animals at day 32 dpi, and the marked decrease at 32 dpi in the T PLP-a-MSH cell-treated animals. GAPDH mRNA expression was used as internal control. For treatment of actively ongoing EAE, PLP139-151-activated T PLP-a-MSH cells or T PLP-hrGFP cells were transferred passively into recipient mice that had been immunized with PLP139-151/CFA 13 dpi. The sera were collected at different time points and frozen (À801C) until use.
Sample preparation, histology and intracellular cytokine staining
At selected time points during and after treatment, representative mice from each group were taken. Mice were killed by CO 2 asphyxiation and immediately perfused via the left ventricle with sterile PBS. The brain and the spinal column of each mouse were removed and snap frozen in liquid nitrogen and kept at À801C until preparation of RNA. Mice were killed on day 32 after immunization for histopathology. Tissues were fixed in 10% buffered formalin. The brain and the spinal cord were dissected and paraffin embedded before staining with hematoxylin and eosin to assess infiltration. The CNS tissue homogenate was centrifuged to remove tissue debris, and the supernatant was stored for analysis. Brain and spinal cord cell suspensions were incubated with collagenase II (1 mg/ml; Sigma, 371C, 20 min), and mononuclear cells were isolated by discontinuous Percoll gradient (Pharmacia, Piscataway, NJ, USA). FACS intracellular cytokines were detected in mononuclear cells isolated from T PLP cells, T PLP-hrGFP cells or T PLP-a-MSH cells treated REAE mice. In order to increase the intracellular concentration of cytokines, cells were stimulated with 50 ng/ml PMA and 500 ng/ml ionomycin for 4 h followed by addition of 10 mg/ml brefeldin A (Sigma, St Louis, MO, USA) during the last 2 h of the incubation. Stimulated cells were stained with CD4-FITC before fixing with 4% paraformaldehyde. Cells were resuspended in permeabilization buffer (PBS, 1% saponin, 1% FCS) and stained with IFN-g-PE (XMG1.2) or IL-4-PE (BVD4-1D11) (BD, PharMingen, 30 min, on ice). The cells were then washed in 1% FCS/PBS, resuspended in 1% formaldehyde and analyzed by flow cytometry. An EIA kit (Phoenix, Pharmaceuticals, Inc., Mountain View, CA, USA) was used to detect the contents of a-MSH in the samples. Quantitative enzyme-linked immunosorbent assay (ELISA) assays for IL-2, IFN-g, IL-10 and TGF-b were performed by using paired mAbs specific for the corresponding cytokines (PharMingen, San Diego, CA, USA), according to the manufacturer's recommendations.
RT-PCR analysis
Total RNA was isolated from cells of the brain and the spinal cord using Trizol reagent (Life Technologies, Gaithersburg, MD, USA) following the manufacturer's instructions. RNA concentration was measured by spectrophotometric absorbance at 260 nm. A total of 2 mg of RNA was reverse transcribed using 200 U/ml of M-MLV (Promega, Madison, WI, USA) and 2 mg of random hexamer primers. Half of the reaction mix (19 ml) was reserved for use as a control without addition of reverse transcriptase. Templates were then amplified in a final volume of 50 ml. Primers for hrGFP, MIP-2g, MCP-1, RANTES and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed with Oligo software. Primer sequence and the size of the reaction products are given in Table 2 . PCR was conducted with 20 ml total volume reaction mixture with 0.4 ml cDNA, 0.5 mM of each primer and Taq DNA polymerase following the manufacturer's instructions (Qiagen, Valencia, CA, USA). The PCR program was as follows: preincubation (941C, 2 min), amplification (30 cycles, 941C, 60 s), annealing (55-581C, 45 s) extension (721C, 60 s) and a final extension (721C, 10 min). PCR products were visualized with ethidium bromide on 1.5% agarose gel.
Statistical analysis
Comparisons of the differences in mean clinical score, mean day of onset, proliferative responses and cytokine profiles were made by using two-tailed Student's t-test. Differences in all percentages were determined using the w 2 test or Fisher's exact test. Values of Po0.05 were considered to be significant.
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